Quality Chemicals set to unveil new paediatric HIV/AIDS drug
Lilian Namagembe, a communications consultant, told New Vision Online on behalf of QCIL that the celebrations, which will take place at the company headquarters in Luzira Industrial Park, are expected to be graced by President Yoweri Museveni as the chief guest.
The company is committed to advancing wellness and is the largest producer of World Health Organisation pre-qualified HIV/AIDS and malaria treatments in the region.
KAMPALA - Kampala-based Quality Chemical Industries Ltd (QCIL) is set to launch a new quality control laboratory and paediatric HIV/AIDS medicine today (October 8, 2025), as part of celebrations marking its 20th anniversary.
Lilian Namagembe, a communications consultant, told New Vision Online on behalf of QCIL that the celebrations, which will take place at the company headquarters in Luzira Industrial Park, are expected to be graced by President Yoweri Museveni as the chief guest.
“This landmark occasion will celebrate two decades of QCIL’s contribution to improving access to quality, affordable medicines in Uganda and the region. The event will also feature the commissioning of the new Quality Control Laboratory and the launch of paediatric HIV/AIDS medicine,” she said.
According to its website, QCIL is a publicly listed pharmaceutical manufacturing company, established in Uganda by Ugandans in 2005.
The company is committed to advancing wellness and is the largest producer of World Health Organisation pre-qualified HIV/AIDS and malaria treatments in the region.
“At QCIL, we believe that health is not merely the absence of illness but the vibrant pursuit of life's possibilities. In Africa, we celebrate vitality and resilience – which is why, for us, it's about thriving, not surviving,” it says.
“Our belief makes us more than manufacturers of quality, affordable medications; we are enablers of ‘Life after well’.”
Qcil manufactures essential medicines, particularly for life-saving treatments such as antiretrovirals (ARVs) for HIV/AIDS, artemisinin-based combination therapies (ACTs) for malaria, and drugs for Hepatitis B, among other therapeutic areas.